Details
Nexium Control provides a course of treatment for relieving symptoms of heartburn, indigestion, and acid reflux. Each pack contains 7 tablets intended for short-term use. These tablets work by reducing stomach acid production, thereby managing discomfort associated with digestive acid-related conditions. It's important to follow the instructions provided for optimal results. GlaxoSmithKline (UK) Trading Limited GSK Consumer Healthcare (IE) Ltd., 980 Great West Road, Brentford, TW8 9GS, U. K. Or: 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.
Show more
Ingredients
Ingredients: Each Gastro-Resistant Tablet contains 20 mg Esomeprazole (as Magnesium Trihydrate). Contains sucrose. See package leaflet for further information. As we are always looking to improve our products, our formulations change from time to time, so please always check the packaging before use.
Directions
Directions for use: Take one tablet once a day. Do not exceed this dose. The tablets should be swallowed whole. Do not chew or crush the tablets. May take 2-3 days for full effect. If your symptoms worsen or do not improve after taking this medicine for 14 days in a row, contact your doctor. Read the package leaflet before use. Oral use. Storage recommendation: Do not store above 30°C. Store in the original package in order to protect from moisture. Keep out of the sight and reach of children.
Powder for injectionControlled clinical studiesPrecautions
Pairiotemplate contains sucrose, which is a stabilizer. Pairiotemplate should be taken with antacids, calcium supplements, iron preparations, macrogol or grapefruit juice when taking continuous or reduced-calorie diet. If you are taking antacids, calcium supplements, calcium phosphate binders, calcium carbonate, aluminium hydroxide, magnesium hydroxide, iron oxide or zinc oxide, or zinc-containing antacids, these should not be taken with sucrose. If you are taking sucrose supplements, contact your doctor. These supplements can lower blood sugar and may cause weight loss. Sucrose is a controlled drug product.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$35.95
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
DescriptionEsomeprazole is an oral medication primarily used to treat a variety of medical conditions. It is commonly used to treat upper and lower respiratory tract conditions such as esophageal reflux disease (GERD) and stomach ulcers caused by dietary agents such as proton pump inhibitors (PPIs). It is also used to treat certain types of esophageal adenocarcinoma (an aggressive type of non-small cell lung cancer) in patients with certain cancers of the stomach and intestines.
Esomeprazole is supplied by different manufacturers, including Healthylife Pharmacy, a independently-owned and operated pharmacy business. Bazaar-reviewed goods are available under the following names: Nexium Esomeprazole (60mg) 30 Tablets x 2 Packs (Healthylife 90) Pack of 2 Tablets (BAS) including Nexium.
Esomeprazole is primarily used to treat certain types of (non-small cell lung cancer). It is also commonly used in combination with other treatments to reduce the risk of recurrence (cancer returning after only one additional operation).
Esomeprazole may also be prescribed for other medical conditions as determined by your doctor. Nexium is also used to treat certain types of esophagitis (inflammation of the esophagus caused by Helicobacter pylori infection).
Esomeprazole is a proton pump inhibitor (PPI) used to treat certain types of stomach, esophagus, and esophageal cancers.
While beneficial, Nexium may cause side effects including:
If you experience any serious side effects, such as chest pain, sudden hearing or vision loss, severe dizziness, fainting, or problems with the heart, proceed to seek medical attention immediately.
If you are allergic to esomeprazole or any other ingredients of this medicine, you should seek immediate medical attention.
Some rare side effects include:
If you are suffering from a hypersensitivity to any of the ingredients of this medication, you should seek immediate medical attention.
A new study suggests that an over-the-counter medication used to treat heartburn may not be effective for people with the condition. In the new study, researchers from the University of Wisconsin-Madison, Wisconsin, used a novel and less expensive treatment to treat people with the condition. Their study, called Nexium and Niumec, involved a combination of esomeprazole magnesium and lansoprazole magnesium (Nexium) capsules. The combination was administered in two groups of people: the first group received Nexium 20 mg (Nexium) and the second group received Nexium 40 mg (Nexium). The researchers measured the amount of acid in the stomach contents of all the patients and found that Nexium reduced the amount of acid in the stomach by approximately 30 percent. The researchers also noted that Nexium also reduced the amount of acid in the stomach by about a half. "We conclude that the use of a new medication that works more effectively in reducing acid levels than other available treatments is not the appropriate treatment for heartburn." The study's findings may help other researchers understand why Nexium is being used to treat the condition. Researchers also found that people who used a new medication in the past were less likely to respond to the treatment.
Nexium and Nexium capsules. (Credit: Momentum/AP)The new study, published in the Journal of Gastroenterology, shows that Nexium and Nexium capsules work in the same way to treat heartburn. The findings, which were based on a larger study that compared the two medications, were published in the journal of the Journal of the American Medical Association.
In the study, researchers compared the effects of the two medications for people with the condition. The researchers also looked at the impact of using Nexium and Nexium capsules on people's heartburn scores and found that people who took the new medication had better overall quality of life. The study's authors said the new study's findings could help researchers understand how certain medications can affect patients differently and may lead to new treatments. The study is one of several that could help scientists and researchers make more definitive statements about whether certain medications could be used to treat heartburn.
The new study was published in the journal of the Journal of the American Medical Association. The Journal of the American Medical Association, which was published in the journal of the American Medical Association, was a peer-reviewed journal of the American Medical Association, and was the first study that looked at the effect of Nexium and Nexium capsules on people with heartburn. The study was led by Dr. Andrew W. Jacobs of the University of Wisconsin-Madison. The University of Wisconsin researchers recruited 18 people over the age of 40 with the condition to participate in a study to determine whether they had experienced heartburn. The people were asked to complete a questionnaire that asked if they felt heartburn was a symptom of heartburn or not. The people were then asked to report their average heartburn scores using a standardized questionnaire. The researchers also asked people to answer questions about their habits, such as drinking, smoking, and exercise. After controlling for the factors that might have affected the people's heartburn, the researchers found that people who took Nexium had improved quality of life and less discomfort in the stomach, compared with those who took a placebo.
The new study is the first to assess whether Nexium and Nexium capsules could be effective for heartburn, a type of stomach ulcer. They were the first study to look at the effect of Nexium and Nexium capsules on people with the condition.
The study, published in the journal of the Journal of the American Medical Association, was led by Dr. The people were then asked to complete a questionnaire that asked if they felt heartburn was a symptom of heartburn or not. The researchers found that people who took Nexium had improved quality of life and less discomfort in the stomach, compared with those who took a placebo. "This study provides evidence that the new medication used to treat heartburn is not the appropriate treatment for heartburn," said Dr. Jacobs. "The study shows that a medication that works more effectively in reducing acid levels than other available treatments is not the appropriate treatment for heartburn."
The new study was sponsored by the University of Wisconsin. The study was approved by the Wisconsin Human Research Committee and the Wisconsin Clinical Research and Education Commission.
For more information, click the links below:
https://www.canadapharmacy.The global nexium market was valued at USD 3.27 billion in 2023 and is projected to reach USD 3.54 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 4.8% from 2024 to 2033[1].
The esomeprazole market was valued at USD 1.63 billion in 2024 and is expected to grow at a CAGR of 6.0% during the forecast period. This growth is driven by increasing healthcare expenditure, expanding prescription healthcare facilities, and increasing awareness about esomeprazole's value for patients[1].
However, the colchicine market was valued at USD 1.1 billion in 2024 and is expected to grow at a CAGR of 6.5% from 2024 to 2033[1].
The lansoprazole market was valued at USD 1.2 billion in 2024 and is expected to grow at a CAGR of 6.5% during the forecast period. This growth is attributed to increasing healthcare expenditure, expanding prescription healthcare facilities, and increasing awareness about esomeprazole's value for patients[1].
The prazolamide market was valued at USD 1.1 billion in 2024 and is expected to grow at a CAGR of 3.0% during the forecast period. This growth is influenced by increasing healthcare expenditure, expanding prescription healthcare facilities, and increasing awareness about prazolamide's value for patients[1].
Asia Pacific is the largest market for esomeprazole, with a projected market size of $14.9Bg by 2022. This growth is supported by increasing healthcare expenditure, expanding prescription healthcare facilities, and increasing awareness about esomeprazole's growing potential[1].
The rise of healthcare systems like hospitals, clinics, and specialty clinics contributes to this growth[1][3].
Improved healthcare reimbursement policies, expanding prescription healthcare facilities, and the integration of digital healthcare services into prescription medicines administration, have contributed to this trend[3].
The availability of over-the-counter and prescription medications, facilitated by strategic over-the-counter programs and government initiatives, has positioned esomeprazole to be a widely accessible treatment option for patients[3].
The increasing accessibility of esomeprazole across healthcare systems, increased healthcare expenditure, and the inclusion of prazolamide in prescription medicines administration, has led to a rise in the quantity and quality of healthcare delivered through digital healthcare services[3].
Over-the-counter and prescription medications, facilitated by strategic over-the-counter programs, and government initiatives, have been a major factor in driving this growth[3].
Esomeprazole, a proton pump inhibitor, is recognized for its role in addressing nonserious gastrointestinal conditions, such as non-alcoholic steatohepatitis (NASH), and gastrointestinal bleeding associated with proton pump inhibitors (PPIs). Esomeprazole belongs to a class of drugs known as PPI antibiotics. It is indicated for patients with gastrointestinal symptoms due to Proton Pump Inhibitors (PPIs) or Zollinger-Ellison syndrome associated with proton pump inhibitors (PPIs). These gastrointestinal symptoms can be caused by a range of factors, including impaired gut motility, dysbiosis, and other conditions[3].
The global esomeprazole market, which includes prazolamide, is valued at around around 40% share in various pharmaceutical companies. This high share reflects the growing demand for esomeprazole across various therapeutic areas, driven by increasing healthcare expenditure and expanding prescription healthcare facilities[3].
This segment has demonstrated significant market share over other products with similar therapeutic uses[3].
Multinational companies like Pfizer are used to major markets like the Asia-Pacific region, as well as Europe and North America. These markets provide access to healthcare through various distribution channels, including retail pharmacies and online stores[1].
The esomeprazole market is segmented by product type, including tablets, capsules, and others.
Stade de France Pharmacy